Expression and clinical significance of colorectal cancer stem cell marker EpCAMhigh/CD44+ in colorectal cancer

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1544-1548

  Liu, Dan ^a   Sun, Jinghua ^a   Zhu, Jinming ^b   Zhou, Huan ^a   Zhang, Xian ^a   Zhang, Yang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DALIAN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Double immunohistochemical staining; Stem cells

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER STEM CELL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PROTEIN EXPRESSION; VERY ELDERLY;

EID: 84896262261     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1907     Document Type: Article

References (27)

1. Yamaki M, Shinozaki K, Sakaguchi T, Meseck M, Ebert O, Ohdan H and Woo SL: The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer. Int J Mol Med 31: 299-306, 2013.
2. Christ B and Stock P: Mesenchymal stem cell-derived hepatocytes for functional liver replacement. Front Immunol 3: 168, 2012.
3. Lakowski J, Han YT, Pearson RA, et al: Effective transplantation of photoreceptor precursor cells selected via cell surface antigen expression. Stem Cells 29: 1391-1404, 2011.
4. Dalerba P, Dylla SJ, Park IK, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163, 2007.
5. Lugli A, Iezzi G, Hostettler I, et al: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.Br J Cancer 103: 382-390, 2010.
6. Piscuoglio S, Lehmann FS, Zlobec I, et al: Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater. J Clin Pathol 65: 140-145, 2012.
7. Fléjou JF: WHO Classification of digestive tumors: the fourth edition. Ann Pathol 31: S27-S31, 2011 (In French).
8. Aust DE: WHO classification 2010 for the lower gastrointestinal tract: what is new? Pathologe 32: 326-331, 2011 (In German).
9. Lin Y, Zhong Y, Guan H, Zhang X and Sun Q: CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. J Exp Clin Cancer Res 31: 59, 2012.
10. Haraguchi N, Inoue H, Tanaka F, et al: Cancer stem cells in human gastrointestinal cancers. Hum Cell 19: 24-29, 2006.
11. Sankpal NV, Mayfield JD, Willman MW, Fleming TP and Gillanders WE: Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res 13: R124, 2011.
12. Lin CW, Liao MY, Lin WW, Wang YP, Lu TY and Wu HC: Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem 287: 39449-39459, 2012.
13. Gaiser MR, Lämmermann T, Feng X, et al: Cancer-associated epithelial cell adhesion molecule (EpCAM; CD326) enables epidermal Langerhans cell motility and migration in vivo. Proc Natl Acad Sci USA 109: E889-E897, 2012.
14. Jaggupilli A and Elkord E: Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012: 708036, 2012.
15. Murai T, Maruyama Y, Mio K, Nishiyama H, Suga M and Sato C: Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration. J Biol Chem 286: 1999-2007, 2011.
16. Zarrabi K, Dufour A, Li J, et al: Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem 286: 33167-33177, 2011.
17. Kemper K, Grandela C and Medema JP: Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 1: 387-395, 2010.
18. Schulenburg A, Cech P, Herbacek I, Marian B, Wrba F, Valent P and Ulrich-Pur H: CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol 213: 152-160, 2007.
19. Strauss R, Li ZY, Liu Y, et al: Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 6: e16186, 2011.
20. Belov L, Zhou J and Christopherson RI: Cell surface markers in colorectal cancer prognosis. Int J Mol Sci 12: 78-113, 2010.
21. Wang SJ and Bourguignon LY: Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol 178: 956-963, 2011.
22. Kuhn S, Koch M, Nübel T, et al: A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 5: 553-567, 2007.
23. Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8: 784-804, 2008.
24. Dylla SJ, Beviglia L, Park IK, et al: Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3: e2428, 2008.
25. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H, Costea DE and Mackenzie IC: Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 71: 5317-5326, 2011.
26. Münz M, Murr A, Kvesic M, et al: Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int 10: 44, 2010.
27. Bezan A, Hohla F, Meissnitzer T, et al: Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. BMC Cancer 13: 618, 2013.